posted
Keeping an eye on this one tomm. Results and progress could be better than they have stated.
Reykjavik, Iceland, January 8, 2007 deCODE Advancing Lead Product Development Programs Completes latest clinical trials for heart attack, anti-platelet compounds, preparing to launch first DNA-based diagnostic test
deCODE genetics (Nasdaq:DCGN) today provided an update on recent progress in its lead product development programs. The company will provide additional details on its programs, upcoming milestones and financial outlook in its webcast presentation to be delivered at the JP Morgan Healthcare Conference on Thursday, January 11, at 11:30am PST/2:30pm EST.
deCODE’s lead product candidates include:
* DG041. In late December deCODE completed its Phase IIa trial for DG041, the company’s novel, oral, first-in-class anti-platelet compound being developed as a lesion-specific means of preventing arterial thrombosis without increasing bleeding time. The dose-ranging Phase IIa trial is examining safety and efficacy in platelet inhibition using biomarkers related to atherosclerosis. The company expects to present data from the trial in the second quarter 2007. * DG051. The company completed in December the Phase I single-dose study of DG051, being developed for the prevention of heart attack. Top line results from this trial show DG051 to be safe and well tolerated at all doses tested; with a favorable pharmacokinetic profile potentially suited to once-a-day dosing; and to provide dose-dependent lowering of levels of leukotriene B4, the product of the leukotriene pathway that deCODE’s genetics work has linked to risk of heart attack. The company expects to begin a multiple-dose Phase I study in the coming weeks. * DG031. The company is evaluating formulation and process combinations to develop new tablets of DG031, the company’s Phase III compound targeting the leukotriene pathway for the prevention of heart attack. deCODE suspended its Phase III trial of DG031 last fall due to tablet manufacturing issues, and the company’s manufacturing schedule is to have sufficient clinical supplies to restart Phase III testing by the end of this year. deCODE is also examining the feasibility of resuming testing of DG031 with a once-a-day dosing regimen. * Diagnostics. deCODE expects to complete the CLIA certification process for its DNA diagnostic reference laboratory in the first quarter of this year, and to begin to offer its first test, for variants in the TCF7L2 gene conferring risk of type 2 diabetes, in the second quarter. The company is also advancing the development of reference laboratory tests for prostate cancer, atrial fibrillation and stroke, heart attack, and breast cancer, and is concurrently developing DNA-based diagnostic test kits for several diseases under its alliance with Illumina.
Posts: 76 | From: CHARLOTTE, NC | Registered: Jan 2006
| IP: Logged |
posted
That's what I was thinking but am hoping for an overreaction tomm. and buy in at a low dip. But we will see tomm. how low she goes.
Posts: 76 | From: CHARLOTTE, NC | Registered: Jan 2006
| IP: Logged |
posted
Nothing special so far. Just re-iterating what they have already discovered so far.
Posts: 76 | From: CHARLOTTE, NC | Registered: Jan 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Today, DCGN has been showing support around $1.1 and resistance in the $2.49 range. The buy rating is set to 2 with the $3.28 target price. http://www.9trading.com/Posts: 40 | From: canada | Registered: Jan 2008
| IP: Logged |
posted
delisted and restricted by scottrade for online buys. hmmmmmm .41
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
quote:Originally posted by Rockster: What do you think about this boodog.. its on the nasdaq
I was only bringing it forward to show it was moving. Could very well end up right back in the .20's. Haven't done any dd on this since April. Scottrade must be short on it (IMO) so they have it restricted.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
